CN1064048C - Five compounds of Qingyang ginseng glucoside and its preparation method and application - Google Patents
Five compounds of Qingyang ginseng glucoside and its preparation method and application Download PDFInfo
- Publication number
- CN1064048C CN1064048C CN96112803A CN96112803A CN1064048C CN 1064048 C CN1064048 C CN 1064048C CN 96112803 A CN96112803 A CN 96112803A CN 96112803 A CN96112803 A CN 96112803A CN 1064048 C CN1064048 C CN 1064048C
- Authority
- CN
- China
- Prior art keywords
- glucoside
- extract
- cynanchum
- preparation
- methyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930182478 glucoside Natural products 0.000 title claims abstract description 227
- 150000008131 glucosides Chemical class 0.000 title claims abstract description 222
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- 241000208340 Araliaceae Species 0.000 title description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 title description 2
- 235000008434 ginseng Nutrition 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 41
- 208000006454 hepatitis Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- -1 glucoside glucoside Chemical class 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 101
- 241000587240 Cynanchum Species 0.000 claims description 72
- 239000000284 extract Substances 0.000 claims description 61
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 44
- 238000004440 column chromatography Methods 0.000 claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000741 silica gel Substances 0.000 claims description 24
- 229910002027 silica gel Inorganic materials 0.000 claims description 24
- 230000000857 drug effect Effects 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 238000005238 degreasing Methods 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000012467 final product Substances 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 14
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 8
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 206010019759 Hepatitis chronic persistent Diseases 0.000 claims description 2
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 8
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 229930182470 glycoside Natural products 0.000 abstract 2
- 150000002338 glycosides Chemical class 0.000 abstract 2
- QZMAEZWZCGBZFK-AOJWCAIYSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2s,3r Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QZMAEZWZCGBZFK-AOJWCAIYSA-N 0.000 abstract 1
- QZMAEZWZCGBZFK-UHFFFAOYSA-N 28-(beta-D-Glucopyranosyloxy)-28-oxoolean-12-en-3beta-yl 3-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosiduronic acid Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC(C1O)OC(C(O)=O)C(O)C1OC1OC(CO)C(O)C(O)C1O QZMAEZWZCGBZFK-UHFFFAOYSA-N 0.000 abstract 1
- KPJWZUAARPJYSB-UHFFFAOYSA-N glycoside C Natural products CC1(C)OC(=O)C23CCC1C2(O)CCC(C1(CCC24)C)(C)C3CCC1C2(C)CCCC4(C)COC(C(C(O)C1O)OC2C(C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O KPJWZUAARPJYSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940014569 pentam Drugs 0.000 abstract 1
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 abstract 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 42
- 230000000694 effects Effects 0.000 description 19
- 239000000843 powder Substances 0.000 description 14
- 241000299680 Cynanchum otophyllum Species 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000013256 coordination polymer Substances 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- GOYBREOSJSERKM-DSYKOEDSSA-N D-cymarose Chemical compound O=CC[C@H](OC)[C@H](O)[C@@H](C)O GOYBREOSJSERKM-DSYKOEDSSA-N 0.000 description 3
- GOYBREOSJSERKM-UHFFFAOYSA-N D-oleandrose Natural products O=CCC(OC)C(O)C(C)O GOYBREOSJSERKM-UHFFFAOYSA-N 0.000 description 3
- 208000027530 Meniere disease Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000024255 Audiogenic seizures Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000000881 depressing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- DBDJCJKVEBFXHG-UHFFFAOYSA-N L-Oleandrose Natural products COC1CC(O)OC(C)C1O DBDJCJKVEBFXHG-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- DBDJCJKVEBFXHG-BNHYGAARSA-N Oleandrose Natural products O(C)[C@H]1[C@H](O)[C@H](C)O[C@H](O)C1 DBDJCJKVEBFXHG-BNHYGAARSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- 229960001392 betahistine hydrochloride Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- GOYBREOSJSERKM-ACZMJKKPSA-N oleandrose Chemical compound O=CC[C@H](OC)[C@@H](O)[C@H](C)O GOYBREOSJSERKM-ACZMJKKPSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
涉及青阳参甙丙、甙丁、甙戊、甙已、甙庚五个化合物，及其制备方法和在制药领域中尤其在制备抗肝炎药物中和抗美尼尔氏病药物中的应用。具药源广、药效高、毒性低、稳定性好、生物吸收利用度高的优点；同时提供该药物的制备方法。The invention relates to five compounds of qingyangshen glycoside C, glucoside D, glycoside pentam, glucoside glucoside and glycoside G, their preparation methods and their application in the pharmaceutical field, especially in the preparation of anti-hepatitis drugs and anti-Ménière's disease drugs. The invention has the advantages of wide drug source, high drug efficacy, low toxicity, good stability and high bioabsorption and availability; meanwhile, a preparation method of the drug is provided.
Description
The present invention relates to Cynanchum otophvllum glucoside third, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside five compounds in heptan, and preparation method thereof and in pharmacy field especially in the preparation Antihepatitis medicament and the application in the anti-Meniere's medicine.
The general formula of five compounds that the present invention relates to is:
Compound 1 (Cynanchum otophvllum glucoside third)
Five compounds of the tool said structure formula that extraction separation obtains from Asclepiadaceae Cynanchum plant Cynanchum otophvllum all do not have bibliographical information.
The object of the present invention is to provide five kinds of new compound Cynanchum otophvllum glucosides third that from the Cynanchum otophvllum plant, obtain, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside heptan, their preparation method, and the particularly application in anti-hepatitis of preparation and anti-Meniere's medicine in pharmacy field.
The method of the logical formula I compound of preparation provided by the present invention is to adopt vegetable chemistry method extraction separation from the plant Cynanchum otophvllum.
Concrete, above-mentioned preparation method gets Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchumotophyllum Schneid) root, extract 2-3 time 60-70 ℃ of heat with chloroform, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, getting substrate is the thick glucoside block in drug effect position, uses CCL4-AcoEt (95: 5; 85: 15v/v) extract successively (95: 5v/v) extract and (85: 15v/v) extract, the latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.
Another kind of preparation method of the present invention gets Asclepiadaceae suede Calamus plant Cynanchum otophvllum (Cynanchumotophyllum Schneid) root, extract 2-3 time 60-70 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, getting substrate is the thick glucoside block in drug effect position, uses CCL4-AcoEt (95: 5; 85: 15v/v) extract successively (95: 5v/v) extract and (85: 15v/v) extract, the latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.
The present invention provides the application of logical formula I compound in the preparation Antihepatitis medicament simultaneously.
Above-mentioned application, the especially application in the medicine of preparation treatment chronic persistent hepatitis and chronic hepatitis disease.
The present invention provides the application of logical formula I compound in preparation anti-Meniere's medicine in addition.
Hepatitis is the difficult and complicated illness of harm humans life and health, at present both at home and abroad the development Antihepatitis medicament is mainly from two class medicines--and developing antiviral, immunopotentiating agent or the immunomodulator, is being ucleosides and Sulfate of polysaccharide class at the antiviral drug of clinical study just in the recent period; Immunopotentiating agent is Interferon, rabbit and vegetable polysaccharides body, and it is more sure that for example deoxidation Zovirax and alpha-interferon share the clinical effectiveness for the treatment of hepatitis B.Other medicines still do not have breakthrough progress.But said medicine mostly has bigger toxic side effect, nucleotide drug, particularly some quite serious toxic side effect appear in the alpha-interferon clinical application, according to Giustina etc. at document Giustina et al:Ital J.Gastroenterol, 26:203, report in 1994 is used alpha-interferon treatment chronic viral hepatitis and spirit depressing occurred, side effects such as autoimmune disorder, diabetes, cardiovascular disorder, hemolytic anemia, minority is died from various organ failures.Therefore develop the curative effect height, treatment hepatitis medicament that toxic side effect is little has become urgent problem.And Meniere is a kind of common frequently-occurring disease, and morbidity is 0.5% of a total population, and the whole world has 2500-3000 ten thousand beautiful patients Ni Ershi, middle aged women number in the majority approximately.This disease is a kind of paroxysmal disease, and its symptom comprises that paroxysmal dizzy, nausea and vomiting, eyeball are stayed looks or tremble, and some also has fluctuation deafness, tinnitus and ear sensation of fullness, and a few patients (about 20% patient) stays disable vertigo and forfeiture hearing.This disease is not because of still having at present definite pathological study, the effective medicine of therefore not suiting the medicine to the illness.U.S. nile disease claims Mei Nier syndrome (Menier ' syndrome), be the imprecise difficult and complicated illness of not having the harm humans health of active drug again of a kind of cause of disease again.The world selects some kinds of medicines to carry out exploratory treatment clinically from scopolamine, dimenhydrinate, Anisodamine, promethazine hydrochloride, coromegine, betahistine hydrochloride (betahistine), meclizine medicines such as (mecligine) at present, and effect can not be satisfactory.And said medicine mostly has bigger toxic side effect, and long-term pharmacological agent has irreversible toxic side effect, as deaf and regular tinnitus etc.Therefore develop the curative effect height, treatment Meniere's medicine that toxic side effect is little has become urgent problem.The present invention is based on this, from the Cynanchum otophvllum plant extraction separation have anti-hepatitis and an active new drug composition of anti-Meniere's disease, with five kinds of compounds shown in the logical formula I.
Compound 1 Cynanchum otophvllum glucoside third molecular weight of the present invention is 630, white powder, and fusing point is 159-162 ℃, is dissolved in ethanol or other organic solvent.
Compound 2 Cynanchum otophvllum glucoside fourth molecular weight of the present invention are 1056, white powder, and fusing point is 154-157 ℃, is dissolved in ethanol or other organic solvent.
Compound 3 Cynanchum otophvllum glucosides penta molecular formula of the present invention is C48H76O16, and molecular weight is 908, and white powder is dissolved in ethanol or other organic solvent.
Compound 4 Cynanchum otophvllum glucoside molecular formula in the sixth of the twelve Earthly Branches of the present invention are C48H76O16, and molecular weight is 908, and white powder is dissolved in ethanol or other organic solvent.
Compound 5 Cynanchum otophvllum glucoside molecular formula in heptan of the present invention are C44H70O16, and molecular weight is 854, and white powder is dissolved in ethanol or other organic solvent.
For understand essence of the present invention better, following immune pharmacology, toxicity with Cynanchum otophvllum glucoside third, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside compound in heptan illustrates its new purposes and beneficial effect thereof in the medicine of anti-hepatitis disease of preparation and anti-Meniere's disease.
Adopt Cynanchum otophvllum glucoside third that embodiments of the invention make, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside to be used for following experiment heptan:
One, acute toxicity test:
50 of rats, be divided into 5 groups at random, every group 10, irritate the starch suspension that stomach gives the Cynanchum otophvllum glucoside third of various dose or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan, observe toxicity symptom and all mortality ratio, ask medium lethal dose (LD50) by simplifying probit method, Cynanchum otophvllum glucoside third is 115mg/kg, and Cynanchum otophvllum glucoside fourth is 110mg/kg, and Cynanchum otophvllum glucoside penta is 120mg/kg, Cynanchum otophvllum glucoside the sixth of the twelve Earthly Branches is 118mg/kg, and Cynanchum otophvllum glucoside heptan is 124mg/kg.
The acute poisoning symptom is mainly excitement and dyskinesia, and recurrent tonic convulsion is a feature.
Two, sub-acute toxicity test:
Get 15-18 and restrain mouse 120 grams that then wean, male and female half and half, by body weight, sex random packet, every group 30, first, second and third group is irritated stomach respectively and is given about 1/10,1/20 and the starch suspension in the Cynanchum otophvllum glucoside third of 1/30LD50 or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan, and control group is given regularly feeding of starch slurry, continuous 60 days, experimental session is weighed once every day, gets 1/3 animal when experiment finishes and does routine blood test and renal function (NPN) inspection.1/3 animal is cooked liver function (SGPT) and checks, 1/3 animal is observed after giving over to drug withdrawal, when observing blood picture and hepatic and renal function, carries out dirty and testis is weighed and obtained the organ pipe coefficient, and to the visual inspections such as gland, brain and testis of the heart, liver, spleen, lung, kidney, kidney.
In bimestrial subacute toxicity test, Cynanchum otophvllum glucoside third or glucoside fourth or glucoside penta or glucoside glucoside in the sixth of the twelve Earthly Branches dosage in heptan integral dose reach 5-6 times of LD50, most growth of animal are normal, show the oral no tangible cumulative effect of this medicine, but the big white mouse abdominal injection observed cumulative effect; Animal body body weight, red, total white blood cells, renal function and internal organs all there is not tangible detrimentally affect; Also observe in the experiment, Cynanchum otophvllum can change the ratio of lymphocyte and neutrophil, lymph is reduced and the neutrophil rising, but total white blood cells is not had obvious influence.
Three, the immune pharmacological action of anti-hepatitis:
With animal (mouse body weight 18-22 gram) random packet, every group 10, Cynanchum otophvllum glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside add endoxan group (being called for short the Cynanchum otophvllum group) heptan, solvent polyoxyethylene glycol (PEG) adds endoxan group (being called for short the CP group), and blank group injecting normal saline every day 0.2ml/ only.The Cynanchum otophvllum group is by 1/4 LD50 (70mg/kg) intramuscular injection every day, endoxan was pressed the 100mg/kg subcutaneous injection once on 10th, in experiment the 1st, 14,17,24,31 by tail vein blood mensuration total white blood cells, lymphocyte per-cent, ANAE positive lymphocyte per-cent, lymphocyte DNA content (pressing point-score):
1, to the influence of ANAE positive lymphocyte:
After giving CP the 4th day, CP group ANAE positive lymphocyte per-cent changed little, but its absolute number obviously descends, and dropped to minimum level on 7th behind injection CP, recovered normal then gradually; The decline in the 4th day behind injection CP of Cynanchum otophvllum group ANAE positive lymphocyte is not remarkable, drops to lower-most point on 7th yet, is evident as light but the decline degree is single with the CP group.
2, to the provide protection of lymphocyte DNA:
The content of CP group lymphocyte DNA began on 4th to descend, and dropped to minimum level on the 7th.The Cynanchum otophvllum group also is to begin in 4th to descend, and drops to lower-most point by 7 days, but all is significantly higher than the CP group.The dynamic change of lymphocyte DAN, the decline of the DNA value of CP group is rapid, and continues for some time; Though the dna content of Cynanchum otophvllum group has decline, the time generation that sharply descends is later, keeps the time weak point of the lower-most point of decline, with regard to bottom out.A large amount of cavitys all appear in CP group and PEG group lymphocyte nuclear dna colour attaching area, and the Cynanchum otophvllum group is not observed this phenomenon, and visible Cynanchum otophvllum has provide protection to lymphocyte DNA.
3, to the hepatitis patient Immune Effects:
Cynanchum otophvllum glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside are treated delay property chronic hepatitis 44 examples respectively heptan, wherein extract 19 examples out and done the PHA tuerculoderma before and after treatment, and the mean diameter of blush is in the positive reaction of the above person of 14mm.The result is: having 2 examples to be the skin test feminine gender before the treatment, is 9.5mm before the 1 example treatment, rises to 16.5mm after the treatment, reaches clinical cure.Before the 1 example treatment is 5mm, rises to mean diameter 10.5mm after the treatment.(mean diameter is 14.5,16.0,15mm), rising is arranged all after the treatment, and its mean diameter is respectively 21.5mm, 17.5mm, 24mm to treat the positive weak reaction of preceding 3 examples.All at the positive reaction high level, there are 5 routine mean diameters that the 1-4mm of dwindling is arranged slightly after the treatment before other 14 example treatment, 2 routine no changes, 7 routine mean diameters increase from 5.5-16.5mm.19 examples before and after treatment the PHA mean diameter relatively, there were significant differences (t=3.1855，d．f=19-1=18，t18．005=2．101?p＜0．05)。Above result shows that Cynanchum otophvllum can make the PHA skin test reaction of hepatitis transfer the positive to, and high reactor is decreased, and prompting has regulating effect to the T lymphocyte.
Four, anti-Meniere's disease immunity pharmacological action
1, anti-audiogenic seizure
The experiment P of audiogenic seizure sensitivity
π-PMc rat, male and female are all used, random packet, every group 10, body weight 200-270 gram is at first measured outbreak susceptibility, continuous 3 days, react constant and in experiment, the ip this product of then dividing into groups is surveyed its anticonvulsion effect again after 4 hours, to prevent that fully outbreak from being index, calculate its ED50, the result proves that the ED50 of glucoside third is 10.8mg/kg, and the ED50 of glucoside fourth is 11.2mg/kg, the ED50 of glucoside penta is 10.5mg/kg, the ED50 in glucoside the sixth of the twelve Earthly Branches is 12.2mg/kg, and the ED50 in glucoside heptan is 10.8mg/kg, and consumption has made outbreak obviously alleviate (P＜0.01) when 6.0-7.0mg/kg.
Take a broad view of above experimental result, beneficial effect of the present invention is:
Cynanchum otophvllum glucoside third of the present invention, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside tool in heptan medicine source is wide, drug effect is high, toxicity is low, good stability, advantage that the bio-absorbable availability is high:
Cynanchum otophvllum glucoside third of the present invention, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside have immunocompetence heptan, and toxic side effect is little, and convenient oral is the antihepatitis drug composition of effective low toxicity.Adopt Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root, extract 2-3 time 60-70 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be the thick glucoside block in drug effect position, with CCL4-AcoEt (95: 5; 85: 15v/v) extract successively (95: 5v/v) extract and (85: 15v/v) extract, the latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, again respectively with chloroform+methyl alcohol, methyl alcohol+water mixed liquid wash-out gets Cynanchum otophvllum glucoside third respectively, the glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside heptan, they are different from the single immunocompetence of general immune drug, they work simultaneously to immunity system-nervus centralis-internal secretion, this shows on pharmacology and the clinical effectiveness, collection is suffered from chronic hepatitis all over the body, the patient of impotence and epilepsy takes Cynanchum otophvllum glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside and obtains the curative effect that a medicine is controlled three diseases heptan.Show that this medicinal ingredients oral absorption is good, easy administration.The effective dose of human oral (to moving chronic hepatitis) is 15-20mg/kg (body weight for humans), and its safety ratio is (12.4-16.8 doubly), and efficient is 68%, shows this medicinal ingredients safe ready.Comprehensive above-mentioned chemistry, the result of pharmacology, confirm Cynanchum otophvllum glucoside third, the glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside has immunomodulatory and enhancement heptan, the move chronic hepatitis particularly viral to hepatitis has therapeutic action, it is efficient near nuclear class medicine and alpha-interferon combined treatment effect, all at 68% clinical efficacy, and Cynanchum otophvllum antihepatitis drug, toxic side effect is little: other class medicines mostly have bigger toxic side effect, as nucleotide drug, particularly some quite serious toxic side effect appear in the alpha-interferon clinical application, according to Giustina etc. at document Giustina et al:Ital J.Gastroenterol, 26:203, report in 1994, use alpha-interferon treatment chronic viral hepatitis and spirit depressing occurs, autoimmune disorder, diabetes, cardiovascular disorder, various organ failures are died from side effects such as hemolytic anemia, minority.
In addition, Cynanchum otophvllum glucoside third, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside have immunocompetence heptan, and chloroform is injected the Meniere pathological model (the dizzy rotation of cavy, ocular ataxy, head are vacillated now to the left, now to the right) that causes in cavy external auditory meatus deep good therapeutic action.Efficient is 85-90%, with control group notable difference is arranged; Cynanchum otophvllum glucoside third or glucoside fourth or glucoside penta or glucoside toxic side effect in the sixth of the twelve Earthly Branches are little, and convenient oral is the anti-Meniere's medicine of effective low toxicity.
Embodiment one:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 2 times 70 ℃ of heat with chloroform, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position thick glucoside block 200g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 38 restrains and (85: 15v/v) extract 107.5g successively, the latter uses silica gel column chromatography, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter in silica gel H repeatedly compression leg (1, pump: BuCHI 681Chromatography pump; 2, bolt is surveyed device: BuCHI UV/VIS FILTER-PHOTOMETER; 3, compression leg (Lichrospher 100 Rp-1812 μ m collector: BuCHI 684 Fraction Collector) and among the Rp-18, Made in BERCK) chromatography is more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), methyl alcohol+water (70: 30 and 80: 20) mixed solution wash-out gets final product.Respectively Cynanchum otophvllum glucoside the third 640, glucoside fourth 1020, glucoside penta 520mg, glucoside 560mg in the sixth of the twelve Earthly Branches, glucoside 610mg in heptan.In glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan and vehicle weight ratio is that 1: 2 ratio adds vehicle starch, makes tablet.
Embodiment two:
Obtain Cynanchum otophvllum glucoside third, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside heptan with embodiment one described method, be pressed into the capsule for medicine of packing into behind the powder then and make the Cynanchum otophvllum capsule.
Embodiment three:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 3 times 65 ℃ of heat with chloroform, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position block 250g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 42 restrains and (85: 15v/v) extract 117.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform ten methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) mixed solution Xian took off and gets final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 660mg, glucoside fourth 1100mg, glucoside penta 530mg, glucoside 560mg in the sixth of the twelve Earthly Branches, glucoside 630mg in heptan, formulation method is routinely made glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan the nourushing syrup of one of concentration 0.5g/10ml.
Embodiment four:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 2 times 65 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position block 300g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 45 restrains and (85: 15v/v) extract 127.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 670mg, glucoside fourth 1200mg, glucoside penta 535mg, glucoside 570mg in the sixth of the twelve Earthly Branches, glucoside 640mg in heptan, be 1: 4 ratio adding vehicle starch in glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan and vehicle weight ratio, make tablet.
Embodiment five:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 3 times 70 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position block 300g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 45 restrains and (85: 15v/v) extract 127.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 670mg, glucoside fourth 1200mg, glucoside penta 535mg, glucoside 570mg in the sixth of the twelve Earthly Branches, glucoside 640mg in heptan, be pressed into the capsule for medicine of packing into behind the powder heptan by glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside and make the Cynanchum otophvllum capsule.
Embodiment six:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 3 times 60 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position 250 grams, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 38 restrains and (85: 15v/v) extract 107.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 660mg, glucoside fourth 1100mg, glucoside penta 530mg, glucoside 560mg in the sixth of the twelve Earthly Branches, glucoside 630mg in heptan, formulation method is routinely made glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan the nourushing syrup of one of concentration 0.2g/ml.
Embodiment seven:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 2 times 70 ℃ of heat with chloroform, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position thick glucoside block 200g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 38 restrains and (85: 15v/v) extract 107.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 640mg, glucoside fourth 1020mg, glucoside penta 520mg, glucoside 560mg in the sixth of the twelve Earthly Branches, glucoside 610mg in heptan, be 1: 2 ratio adding vehicle starch in glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan and vehicle weight ratio, make tablet.
Embodiment eight:
Obtain Cynanchum otophvllum glucoside third, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches or glucoside heptan with embodiment seven described methods, be pressed into the capsule for medicine of packing into behind the powder then and make the Cynanchum otophvllum capsule.
Embodiment nine:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 3 times 65 ℃ of heat with chloroform, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position block 250g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 42 restrains and (85: 15v/v) extract 117.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 660mg, glucoside fourth 1100mg, glucoside penta 530mg, glucoside 560mg in the sixth of the twelve Earthly Branches, glucoside 630mg in heptan, formulation method is routinely made glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan the nourushing syrup of one of 0.5g/10ml.
Embodiment ten:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 2 times 65 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position block 300g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 45 restrains and (85: 15v/v) extract 127.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 670mg, glucoside fourth 1200mg, glucoside penta 535mg, glucoside 570mg in the sixth of the twelve Earthly Branches, glucoside 640mg in heptan, be 1: 4 ratio adding vehicle starch in glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan and vehicle weight ratio, make tablet.
Embodiment 11:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 3 times 70 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position block 300g, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 45 restrains and (85: 15v/v) extract 127.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 670mg, glucoside fourth 1200mg, glucoside penta 535mg, glucoside 570mg in the sixth of the twelve Earthly Branches, glucoside 640mg in heptan, press glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan, be pressed into the capsule for medicine of packing into behind the powder and make the Cynanchum otophvllum capsule.
Embodiment 12:
Get Asclepiadaceae Cynanchum plant Cynanchum otophvllum (Cynanchum otophyllum Schneid) root 10kg, extract 3 times 60 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, substrate be drug effect position 200 grams, with CCL4-AcoEt (95: 5; 85: 15v/v) extract to such an extent that (95: 5) extract 38 restrains and (85: 15v/v) extract 107.5g successively, the latter uses silica gel column layer spare, (99: 1,98: 2,95: 5,85: 15v/v) gradient elution, every 1000ml were a, receive 44 parts altogether to use CHCL3, CHCL3-MeOH successively.The latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, more respectively with chloroform+methyl alcohol (98: 2 and 95: 5v/v), (70: 30 and 80: 20v/v) the mixed solution wash-out got final product methyl alcohol+water.Respectively Cynanchum otophvllum glucoside third 660mg, glucoside fourth 1100mg, glucoside penta 530mg, glucoside 560mg in the sixth of the twelve Earthly Branches, glucoside 630mg in heptan, formulation method is routinely made glucoside third or glucoside fourth or glucoside penta or glucoside the sixth of the twelve Earthly Branches or glucoside heptan the nourushing syrup of one of concentration 0.2g/ml.
The physico-chemical property in the glucoside third that makes in the foregoing description, glucoside fourth, glucoside penta, glucoside the sixth of the twelve Earthly Branches, glucoside heptan is as follows:
Glucoside third: be white powder, it is 630 that fusing point 159-162 degree, FAB-MS are measured its molecular weight; UV λ MeoH/max, nm (log ε): 204 (4.2), 259 (4.1); Infrared IRv KBr/maxem13430 (OH), 3400,2930,1690 (c-o) .1585,1505 (aromatic rings), 1475 (CH3), 1270,1230,1195,1160,1075,1045 (c-o-o), 975,850,770, nucleus magnetic hydrogen spectrum (CDCl3) 1.05 (3H, S.ZC19-CH3), 1.23 (3H, d.J=6.4Hz. sugar C6-CH3), 1.50 (3H, S.C18-CH3), 2.08 (3H, S, C21-CH3), 3.52 (1H, S.C3-aH), 4.70 (1H, dd.J1=11.2Hz, J2=4.4Hz, C12-H), 4.87 (1H, d.J=8Hz, sugared Cl-H), 5.3 (1H, S.Ce-H), 6.75,7.73 (4H, dd, J=8.76Hz, 4H on the 1.4-=substituted benzene ring).
The glucoside fourth: be white powder, fusing point 154-157 ℃, it is 1056 that FAB-MS measures its molecular weight; UV λ KBr/max, nm (loge): 206 (4.2), 219 (4.3), 281 (3.2); Infrared IRVKBr/max cm 13450 (OH), 2960,2930 (1440) (OCH3), 1700,1635 (C=CH-CO), 1520,1370,1350,1220,1160,1080,1050 (C-O-O), 1000,980,910,860,750; Nucleus magnetic hydrogen spectrum (CDCl3) 1.06 (6H, d.J=7Hz ,-CH-CH3), 1.13 (3H, S.C19-CH3), 1.19 (3H, d, J=6Hz, sugar C6-CH3), 1.21 (3H, d.J=6Hz, sugared C6-CH3), (1.25 3H, d, J=8Hz, sugared C6-CH3), 1.50 (3H, S, C18-CH3), 2.11 (3H, S.C7-CH3), 2.17 (6H, S. sugar C3-OCH3), 4.31 (1H, m, C3-aH), 4.44 (4H, dd, J=8Hz, 4 sugared Cl-H), 4.56 (1H, dd/J=9Hz.C12-aH), (4.84 4H, t.J=10Hz, 4 sugared C4-H), 5.34 (1H, br.C6-H), 5.53 (1H, S.C2-H).
Glucoside penta: be the unformed powder of white, molecular formula C48H76O16, fusing point 159-162 ℃, MS (m/z): 908 (m+), 633,517,451,359,264,173,145,127.1H-NMR (C5D5N): 6.45 (1H, brd, OH), 5.85 (1H, S, 2-H), 5.45 (ah, S, 6-H), 3.56,3.45 (each 3H, S, 2XOCH3), 2.60 (3H, S, 21-CH3), 2.26 (3H, S, 7-CH3), 1.97 (3H, S, 19-CH3), 1.55,1.43,1.35 (each 3H, d, J=6.0Hz, sugar 6-CH3), 1.30 (3H, S, 18-CH3), 0.93 (6H, d, 5,6-CH3).
Glucoside the sixth of the twelve Earthly Branches: be the unformed powder of white, fusing point 159-162 ℃, molecular formula C48H76O16; MS (m/z): 908,798,716,619,511,359,281,188,127.H-NMR (CDCl3): 5.39 (1H, S, 2-H), 5.23 (1H, S, 6-H), 4.80,4.69 (each 1H, brd, J=9.4Hz, sugared 1-H), 4.39 (2H, brd, J=10.6Hz, 12d-H, sugared 1-H), 4.11 (1H, brs, cymarose 3-H), (3.76 1H, dq, sugared 5-H), 3.31,3.24 (each 3H, S, 2XOCH3), 2.97 (1H, t, oleandrose 4-H), 2.04 (3H, S, 21-CH3), 1.94 (3H, S, 7-CH3), 1.34 (3H, S, 19-CH3), 1.18 (3H, d, J=6.0Hz, sugared 6-CH3), 1.10 (6H, d, J=6.0Hz, sugared 6-CH3), 1.01 (3H, S, 18-CH3), 0.94 (6H, d, J=7.0Hz, 5,6-CH3).
Glucoside heptan: be the unformed powder of white, fusing point 159-162 ℃, molecular formula C44H70O16, MS (m/z): 854 (m+), 794 (M_HOAc), 710 (M+-145+H), 643,582,522,419,357,325,283,255,145,127.H-NMR (C5D5N): 6.53 (1H, S, OH), 6.25 (1H, S, 6-H), 4.95 (1H, dd, J=11.5,3.7Hz, 12a-H), 4.76 (1H, brd, J=8.3Hz, sugared 1-aH), (4.20 2H, dq, two cymarose 5-H), 4.09,4.05 (each 1H, brd, J=2.6Hz, two cymarose 3-H), 3.85 (1H, m, 3a-H), 3.61,3.57,3.47 (each 3H, S, 3XOCH3), 2.46 (3H, S, 21-CH3), 2.05 (3H, S, OAc), 1.93 (3H, S, 18-CH3), 1.57,1.41,1.38 (each 3H, d, J=6.1Hz, sugar 6-CH3), 1.31 (3H, S, 19-CH3).
Claims (6)
1, logical formula I is
Five C21 steroidal glycoside compounds, compound 1 in the formula
R
2=CH
3CO-
2, the preparation method of the said general formula compound of claim 1, it is characterized in that getting Asclepiadaceae Cynanchum plant Cynanchum otophvllum root, extract 2-3 time 60-70 ℃ of heat with chloroform, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, getting substrate is the thick glucoside block in drug effect position, is 95: 5 with CCL4-AcoEt in weight ratio; Successively extract at 85: 15 95: 5 extracts and 85: 15 extracts, the latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, is that 98: 2 and 95: 5, methyl alcohol+water weight ratio are that 70: 30 and 80: 20 mixed solution wash-outs get final product with chloroform+methyl alcohol weight ratio respectively again.
3, the preparation method of the said general formula compound of claim 1, it is characterized in that getting Asclepiadaceae Cynanchum plant Cynanchum otophvllum root, extract 2-3 time 60-70 ℃ of heat with ethyl acetate, reclaim dope behind the solvent with the sherwood oil degreasing that refluxes, getting substrate is the thick glucoside block in drug effect position, is 95: 5 with CCL4-AcoEt in weight ratio; Successively extract at 85: 15 95: 5 extracts and 85: 15 extracts, the latter is through silica gel H medium pressure column chromatography and Rp-18 medium pressure column chromatography repeatedly, is that 98: 2 and 95: 5, methyl alcohol+water weight ratio are that 70: 30 and 80: 20 mixed solution wash-outs get final product with chloroform+methyl alcohol weight ratio respectively again.
4, the application of the general formula compound of claim 1 in the preparation Antihepatitis medicament.
5, application according to claim 4 is characterized in that the application in the medicine of preparation treatment chronic persistent hepatitis and chronic hepatitis disease.
6, the application of the general formula compound of claim 1 in preparation anti-Meniere's medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96112803A CN1064048C (en) | 1996-08-29 | 1996-08-29 | Five compounds of Qingyang ginseng glucoside and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96112803A CN1064048C (en) | 1996-08-29 | 1996-08-29 | Five compounds of Qingyang ginseng glucoside and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1150951A CN1150951A (en) | 1997-06-04 |
| CN1064048C true CN1064048C (en) | 2001-04-04 |
Family
ID=5121611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96112803A Expired - Fee Related CN1064048C (en) | 1996-08-29 | 1996-08-29 | Five compounds of Qingyang ginseng glucoside and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1064048C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1292754C (en) * | 2004-11-09 | 2007-01-03 | 云南白药集团股份有限公司 | Application of C21 steroid glycoside in pharmacy |
| CN101357150B (en) * | 2008-08-29 | 2011-07-20 | 贵州大学 | Method for separating and purifying Qingyangshenylycosides from Qingyangsheny |
| CN101953864B (en) * | 2010-09-29 | 2013-05-22 | 中国人民解放军军事医学科学院毒物药物研究所 | Cynanchum otophyllum aglycone and medical application of extractive containing same |
| CN102550611A (en) * | 2011-01-04 | 2012-07-11 | 昆明华地丰润生物科技有限公司 | Plant rodenticide and preparation method thereof |
| CN102924554B (en) * | 2012-10-29 | 2015-07-22 | 中国科学院昆明植物研究所 | C-3,11,12,20-tetrasubstituted C-21 steroid derivative and its pharmaceutical composition and use in medicine |
| CN110128496A (en) * | 2019-06-06 | 2019-08-16 | 贵州师范大学 | Kodartin saponin composition and its preparation method and use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1053239A (en) * | 1990-01-23 | 1991-07-24 | 哈里尔医学和技术设备销售有限公司 | The production of glucosides, particularly steroid glycoside |
| CN1019935C (en) * | 1987-03-09 | 1993-02-24 | 中国人民解放军空军桂林医院 | Method for extracting sweetening agent from momordica grosvenori |
| CN1028998C (en) * | 1986-09-04 | 1995-06-21 | 美克德株式会社 | Method for preparing sialic acid glycosyl cholesterol |
| CN1108260A (en) * | 1993-12-24 | 1995-09-13 | 三菱化学株式会社 | Sialic acid derivatives |
-
1996
- 1996-08-29 CN CN96112803A patent/CN1064048C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1028998C (en) * | 1986-09-04 | 1995-06-21 | 美克德株式会社 | Method for preparing sialic acid glycosyl cholesterol |
| CN1019935C (en) * | 1987-03-09 | 1993-02-24 | 中国人民解放军空军桂林医院 | Method for extracting sweetening agent from momordica grosvenori |
| CN1053239A (en) * | 1990-01-23 | 1991-07-24 | 哈里尔医学和技术设备销售有限公司 | The production of glucosides, particularly steroid glycoside |
| CN1108260A (en) * | 1993-12-24 | 1995-09-13 | 三菱化学株式会社 | Sialic acid derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150951A (en) | 1997-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1684699A (en) | Process for extracting and purifying active ingredients from honeysuckle stems, their use in anti-inflammatory and analgesic medicines | |
| CN1064048C (en) | Five compounds of Qingyang ginseng glucoside and its preparation method and application | |
| CN1449761A (en) | Medicine for relieving spasm and pain and preparation process thereof | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| CN1733125A (en) | Effective parts of Immature Bitter Orange or trifoliate-orange root-bark or their effective parts composition and preparation method and pharmaceutical purpose thereof | |
| CN1300176C (en) | New saponin and its derivative, its preparation method and its use in medicine | |
| CN1148958A (en) | Pharmaceutical application of glucoside A and B of auricledleaf swallowort | |
| CN1704065A (en) | Pharmaceutical use of hesperidin and/or naringin | |
| CN101293904B (en) | New compound, preparation method and application thereof | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| CN110092806B (en) | C19 diterpene alkaloid glycosides with analgesic effect in aconite and use thereof | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN1081922C (en) | Medicinal composition containing ginsenoside Re, preparation and usage thereof | |
| CN100464755C (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN1398861A (en) | Prepn and application in preparing medicine of Fraxinus general coumarin | |
| CN1733054A (en) | A kind of cornus officinalis extract and its preparation process | |
| CN112279811A (en) | C20Diterpenoid alkaloids, their preparation and use for treating pain related diseases | |
| CN1095669C (en) | Medicine composition of saponin containing protopanaxyndiol component and preparing process and application thereof | |
| CN1628793A (en) | Injectio for activating pulse and its preparing method | |
| CN1224390C (en) | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver | |
| CN1600357A (en) | Effective position of pilose asiabell root, preparation, medication use and preparation method | |
| CN1836665A (en) | Pharmaceutical use of neohesperidin or its composition | |
| CN1839855A (en) | Ginsenoside F1 medicinal uses | |
| CN1167421C (en) | Medicine composition containing pyrroloquinolinequinone for treating saturnism | |
| CN102078346B (en) | Chinese medicinal preparation for relieving heat, resisting inflammation and easing pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |